Puxiu Wang

Prof. Dr. Puxiu Wang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
PWPuxiu Wang
Puxiu Wang
XCXiuxiu Cao
Xiuxiu Cao
CYChu Yang
Chu Yang

15 January 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TRTianyang Ren
Tianyang Ren
JCJin Chen
Jin Chen
PQPan Qi
Pan Qi
PXPeifu Xiao
Peifu Xiao
PWPuxiu Wang
Puxiu Wang

1 November 2018 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
PWPuxiu Wang
Puxiu Wang
YLYue Li
Yue Li
MJMingyan Jiang
Mingyan Jiang

1 November 2016 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
PWPuxiu Wang
Puxiu Wang
QWQian Wang
Qian Wang
TRTianyang Ren
Tianyang Ren
HGHaoyu Gong
Haoyu Gong
JGJingxin Gou
Jingxin Gou
XTXing Tang
Xing Tang

1 December 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
PXPeifu Xiao
Peifu Xiao
PQPan Qi
Pan Qi
JCJin Chen
Jin Chen
ZSZilin Song
Zilin Song
YWYidan Wang
Yidan Wang
PWPuxiu Wang
Puxiu Wang

4 December 2025 in Drug Delivery
Verified
Journal Article
Open access
JLJinguo Li
Jinguo Li
YZYuhao Zhang
Yuhao Zhang
CSChangyu Shao
Changyu Shao
YBYining Bai
Yining Bai
PWPuxiu Wang
Puxiu Wang
TRTianyang Ren
Tianyang Ren
Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer and is characterized by high invasiveness, rapid recurrence, and poor prognosis. To date, the ferroptosis-combined therapies have exerted their potential in the TNBC treatments via multi-mechanisms. Here, we reported a doxorubicin (DOX)-Fe complex and RSL3 co-loaded liposomes (DOX-Fe/RSL3@LIPs) for ferroptosis-enhanced chemotherapy on TNBC tumors. This nanoformulation performed a uniform spherical structure with a mean particle size of 126.9 nm, a zeta potential of -3.56 mV, and high colloidal stability. The pH-responsive dissociation of DOX-Fe and release of DOX were conducive to drug accumulation in the tumor microenvironment and tumor cells, meanwhile efficiently suppressed free DOX leakage in the blood circulation, potentially reducing the cardiotoxicity of DOX. In vitro cell and in vivo pharmacodynamic studies demonstrated a favorable anticancer effect of the DOX-Fe/RSL3@LIPs on 4T1 tumors by synchronously delivering biologically active DOX, Fe2+, and RSL3 to the tumor sites. DOX induced tumor cell death through a dual pathway of apoptosis/ferroptosis, and promoted the H2O2 generation. The tumor cell ferroptosis was observably enhanced via supplements of the ferrous ions and H2O2, and RSL3-derived GPX4 inhibition to severely destroy the oxidation balance in cells. In this paper, the DOX-Fe/RSL3@LIPs have exerted a synergistic anticancer effect on TNBC by combining ferroptosis and conventional chemotherapy, and made a meaningful exploration of new strategies for TNBC therapy.